Search Results - "BOULIKAS, Teni"

Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin by Boulikas, Teni

“…Nanoparticle formulations for packaging existing drugs have been used to treat cancer. Lipoplatin is a liposomal cisplatin encapsulated into liposome…”
Get more information

Cisplatin and platinum drugs at the molecular level. (Review) by Boulikas, Teni, Vougiouka, Maria

“…Over twenty years of intensive work toward improvement of cisplatin, and with hundreds of platinum drugs tested, has resulted in the introduction of the widely…”
Get more information

Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing rats by Huo, Tianyao, Barth, Rolf F, Yang, Weilian, Nakkula, Robin J, Koynova, Rumiana, Tenchov, Boris, Chaudhury, Abhik Ray, Agius, Lawrence, Boulikas, Teni, Elleaume, Helene, Lee, Robert J

“…The purpose of this study was to evaluate two novel liposomal formulations of cisplatin as potential therapeutic agents for treatment of the F98 rat glioma…”
Get full text

Systemic Lipoplatin Infusion Results in Preferential Tumor Uptake in Human Studies by BOULIKAS, Teni, STATHOPOULOS, Georgios P, VOLAKAKIS, Nikolaos, VOUGIOUKA, Maria

“…Lipoplatinì, a liposomal formulation of cisplatin, was developed with almost negligible nephrotoxicity, ototoxicity and neurotoxicity, as demonstrated in…”
Get full text

Concurrent Liposomal Cisplatin (Lipoplatin), 5-Fluorouracil and Radiotherapy for the Treatment of Locally Advanced Gastric Cancer: A Phase I/II Study by Koukourakis, Michael I., M.D, Giatromanolaki, Alexandra, M.D, Pitiakoudis, Michael, M.D, Kouklakis, George, M.D, Tsoutsou, Pelagia, M.D, Abatzoglou, Ioannis, Ph.D, Panteliadou, Marianthi, M.D, Sismanidou, Kyriaki, M.Sc, Sivridis, Efthimios, M.D, Boulikas, Teni, M.D

“…Purpose Liposomal drugs have a better tolerance profile and are highly accumulated in the tumor environment, properties that promise an optimal…”
Get full text

Putative nuclear localization signals (NLS) in protein transcription factors by Boulikas, T

“…We have recognized about ten distinct forms of strongly basic hexapeptides, containing at least four arginines and lysines, characteristic of nuclear proteins…”
Get more information

Liposomal Oxaliplatin in the Treatment of Advanced Cancer: A Phase I Study by STATHOPOULOS, George P, BOULIKAS, Teni, KOURVETARIS, Andreas, STATHOPOULOS, John

“…Background: Lipoxal is a liposomal oxaliplatin, which reduces the cytotoxic agent's adverse reactions without reducing effectiveness. Our objectives were to…”
Get full text

Viral and Non-viral Vectors in Gene Therapy: Technology Development and Clinical Trials by Lundstrom, Kenneth, Boulikas, Teni

“…Gene therapy as part of modern molecular medicine holds great promise for the treatment of both acute and chronic diseases and has the potential to bring a…”
Get full text

Nature of DNA sequences at the attachment regions of genes to the nuclear matrix by Boulikas, T

“…Matrix-attached regions (MARs) have been demonstrated to nest origins of replication and transcriptional enhancers. A set of 13 rules is proposed aimed at…”
Get more information

Low Renal Toxicity of Lipoplatin Compared to Cisplatin in Animals by DEVARAJAN, Prasad, TARABISHI, Ridwan, MISHRA, Jaya, QING MA, KOURVETARIS, Andreas, VOUGIOUKA, Maria, BOULIKAS, Teni

“…Cisplatin is one of the most widely used and effective chemotherapeutic agents for the treatment of several human malignancies. Although the effectiveness of…”
Get full text

Common structural features of replication origins in all life forms by Boulikas, Teni

“…Origins of replication (ORIs) among prokaryotes, viruses, and multicellular organisms appear to possess simple tri‐, tetra‐, or higher dispersed repetitions of…”
Get full text

Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review) by Boulikas, Teni, Vougiouka, Maria

“…Cisplatin continues to play a central role in cancer chemotherapy in spite of its toxicity. It is used as first-line chemotherapy against epithelial…”
Get more information

Silver staining of proteins in polyacrylamide gels by Wray, W, Boulikas, T, Wray, V P, Hancock, R

Get more information

Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts by Boulikas, Teni

“…Cisplatin has been one of the most widely used and most effective cytotoxic agents in the treatment of malignancies but causes severe adverse reactions…”
Get more information

High affinity MAR-DNA binding is a common property of murine and human mutant p53 by Will, Katrin, Warnecke, Gabriele, Albrechtsen, Nils, Boulikas, Teni, Deppert, Wolfgang

“…We recently reported that murine MethA mutant but not wild‐type p53 specifically binds to MAR‐DNA elements (MARs) with high affinity. Here we show that this…”
Get full text

Electrophoretic separation of histones and high-mobility-group proteins on acid-urea-Triton gels by Boulikas, T

“…The electrophoretic mobilities of calf thymus histones and high-mobility-group (HMG) nonhistone proteins were studied on a newly modified polyacrylamide gel…”
Get more information

Increase in histone poly (ADP-ribosylation) in mitogen-activated lymphoid cells by Boulikas, T, Bastin, B, Boulikas, P, Dupuis, G

“…Poly (ADP-ribosylated) histones appear to be intermediates in nuclear processes that involve DNA strand breaks. We have studied histone ADP-ribosylation in…”
Get more information

Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study by Stathopoulos, George P, Boulikas, Teni, Vougiouka, Maria, Deliconstantinos, George, Rigatos, Sotirios, Darli, Eleftheria, Viliotou, Vasiliki, Stathopoulos, John G

“…Lipoplatin, a new liposomal cisplatin formulation, is formed from cisplatin and liposomes composed of dipalmitoyl phosphatidyl glycerol (DPPG), soy…”
Get more information

Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients : A phase I-II study by STATHOPOULOS, George P, BOULIKAS, Teni, VOUGIOUKA, Maria, RIGATOS, Sotirios K, STATHOPOULOS, John G

“…The present trial is a phase I-II study based on a new liposomal cisplatin (lipoplatin). Previous preclinical and clinical data (phase I pharmacokinetics) led…”
Get full text

Evolutionary consequences of nonrandom damage and repair of chromatin domains by BOULIKAS, T

“…Some evolutionary consequences of different rates and trends in DNA damage and repair are explained. Different types of DNA damaging agents cause nonrandom…”
Get full text